Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M W Deininger

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Leukemia Supplements|May 14, 2016
STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemiaA M Eiring, I L Kraft, B D Page, et al.
Cancer Research|February 11, 1998
Selective induction of leukemia-associated fusion genes by high-dose ionizing radiationM W Deininger, S Bose, J Gora-Tybor, et al.
Blood|July 27, 2000
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistanceF X Mahon, M W Deininger, B Schultheis, et al.
Genes, Chromosomes & Cancer|December 18, 2001
Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogeneS A Vieira, M W Deininger, A Sorour, et al.
Leukemia|November 19, 2011
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitorsE Traer, R MacKenzie, J Snead, et al.
Leukemia|February 13, 2002
High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML)T Köhler, C Schill, M W Deininger, et al.
Leukemia|April 3, 2009
Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutationJ W Tyner, M L Rutenberg-Schoenberg, H Erickson, et al.
Leukemia|November 20, 2015
Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemiaM S Zabriskie, C A Eide, D Yan, et al.
Leukemia|March 21, 2008
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemiaD W Sherbenou, O Hantschel, L Turaga, et al.
Leukemia|May 30, 2008
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemiaA Agarwal, C A Eide, A Harlow, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Leukemia Supplements|May 14, 2016
STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemiaA M Eiring, I L Kraft, B D Page, et al.
Cancer Research|February 11, 1998
Selective induction of leukemia-associated fusion genes by high-dose ionizing radiationM W Deininger, S Bose, J Gora-Tybor, et al.
Blood|July 27, 2000
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistanceF X Mahon, M W Deininger, B Schultheis, et al.
Genes, Chromosomes & Cancer|December 18, 2001
Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogeneS A Vieira, M W Deininger, A Sorour, et al.
Leukemia|November 19, 2011
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitorsE Traer, R MacKenzie, J Snead, et al.
Leukemia|February 13, 2002
High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML)T Köhler, C Schill, M W Deininger, et al.
Leukemia|April 3, 2009
Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutationJ W Tyner, M L Rutenberg-Schoenberg, H Erickson, et al.
Leukemia|November 20, 2015
Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemiaM S Zabriskie, C A Eide, D Yan, et al.
Leukemia|March 21, 2008
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemiaD W Sherbenou, O Hantschel, L Turaga, et al.
Leukemia|May 30, 2008
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemiaA Agarwal, C A Eide, A Harlow, et al.
Pageof 4